Proxygen, a leader in the discovery and development of molecular glue degraders, announced today that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. Proxygen is eligible to receive up to \u20ac495 million ($554 million at the average USD\/EUR FX rate of Q1 2022) in continuous R&D funding, upfront and success-based pre-clinical, clinical, regulatory, and commercial milestones, as well as additional royalty payments. Under the terms of the agreement, the companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.<\/p>\n\n\n\n
This text is a press release from Proxygen. The full text version of the article can be found here<\/a>.<\/p>\n\n\n\n Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH acted as legal advisor to Proxygen. Dr Marco Stief<\/a> and Dr Andreas Ledl<\/a> provided the legal advisory services.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-18051","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte\/18051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":8,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte\/18051\/revisions"}],"predecessor-version":[{"id":18848,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte\/18051\/revisions\/18848"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/media?parent=18051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}